Commentary: Bioequivalence,Interchangeability and Perceptions

Maibach H.I. Maguire H.C. Jr (1969) ‘Interchangeability of methotrexate and cyclophosphamide as inhibitors of allergic contact dermatitis in the guinea pig’, International Archives of Allergy and Immunology, Vol. 35, pp. 535–543.

Gardos G. (1974) ‘Are antipsychotic drugs interchangeable?’, Journal of Nervous and Mental Disease, Vol. 159, pp. 343–348.

Halperin J.A. (1983) ‘Product selection, bioequivalence, and therapeutic equivalence: The generic drug market’, Drug Information Journal, Vol. 17, pp. 73–76.

Meredith P. (2003) ‘Bioequivalence and other unresolved issues in generic drug substitution’, Clinical Therapeutics, Vol. 25, pp. 2875–2890.

Banahan B.F. III Kolassa E.M. (1997) ‘A physician survey on generic drugs and substitution of critical dose medications’, Archives of Internal Medicine, Vol. 157, pp. 2080–2088.

Tse G. Thompson D. Procyshyn R.M. (2003) ‘Generic clozapine: A cost-saving alternative to brand name clozapine?’, Pharmacoeconomics, Vol. 21, pp. 1–11.

Henderson J.D. Esham R.H. (2001) ‘Generic substitution: Issues for problematic drugs’, Southern Medical Journal, Vol. 94, pp. 16–21.

Reiffel J.A. (2000) ‘Formulation substitution and other pharmacokinetic variability: Underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice’, American Journal of Cardiology, Vol. 85, p. 25.

Sabatini S. Ferguson R.M. Helderman J.H. (1999) ‘Drug substitution in transplantation: A National Kidney Foundation White Paper’, American Journal of Kidney Diseases, Vol. 33, pp. 389–397.

Burns M. (1999) ‘Management of narrow therapeutic index drugs’, Journal of Thrombosis and Thrombolysis, Vol. 7, pp. 137–143.

Vasquez E.M. Min D.I. (1999) ‘Transplant pharmacists' opinions on generic product selection of critical-dose drugs’, American Journal of Health System Pharmacy, Vol. 56, pp. 615–621.

Palylyk-Colwell E. Jamali F. Dryden W. (1998) ‘Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion’, Journal of Pharmacy and Pharmaceutical Sciences, Vol. 1, pp. 2–7.

Ansbacher R. (1991) ‘Interchangeability of low-dose oral contraceptives. Are current bioequivalent testing measures adequate to ensure therapeutic equivalency?’, Contraception, Vol. 43, pp. 139–147.

Barrett J.S. Batra V. Chow A. (2000) ‘PhRMA perspective on population and individual bioequivalence’, Journal of Clinical Pharmacology, Vol. 40, pp. 561–570.

Hauck W.W. Anderson S. (1994) ‘Measuring switchability and prescribability: When is average bioequivalence sufficient?’, Journal of Pharmacokinetics Biopharmaceutics, Vol. 22, pp. 551–564.

Midha K.K. Rawson M.J. Hubbard J.W. (1999) ‘Prescribability and switchability of highly variable drugs and drug products’, Journal of Controlled Release, Vol. 62, pp. 33–40.

Schreiber S.L. (2003) ‘Dollars and Sense: Pharmaceutical Product Design is Becoming Vivid’, LEDA at Harvard Law School.